Priorities for transgender medical and healthcare research

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 2, 2016, Pages 180-187

  Feldman, Jamie ^a   Brown, George R ^b   Deutsch, Madeline B ^c   Hembree, Wylie ^d   Meyer, Walter ^e   Meyer Bahlburg, Heino F L ^f   Tangpricha, Vin ^g   T'Sjoen, Guy ^h   Safer, Joshua D ⁱ  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b East Tennessee State University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f Columbia University Medical Center ^*  (United States)

^g Department of Medicine   (United States)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health Disparities; Health Research; Medical Outcomes; Transgender

Indexed keywords

LIPID;

CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; FERTILITY; HEALTH CARE; HEALTH DISPARITY; HEALTH SERVICE; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIFESPAN; MEDICAL RESEARCH; MENTAL HEALTH; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT CARE; RESEARCH PRIORITY; REVIEW; SEXUAL FUNCTION; SYSTEMATIC REVIEW (TOPIC); TRANSGENDER; TRANSLATIONAL RESEARCH; ADVERSE EFFECTS; COMORBIDITY; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; MALE; MINORITY GROUP; MINORITY HEALTH; NEEDS ASSESSMENT; PSYCHOLOGY; RISK FACTOR; SEX REASSIGNMENT; TRANSSEXUALISM;

BIOMEDICAL RESEARCH; COMORBIDITY; DELIVERY OF HEALTH CARE; FEMALE; HEALTH PRIORITIES; HEALTH SERVICES NEEDS AND DEMAND; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; MALE; MINORITY GROUPS; MINORITY HEALTH; NEEDS ASSESSMENT; RISK FACTORS; SEX REASSIGNMENT PROCEDURES; TRANSGENDER PERSONS; TRANSSEXUALISM;

EID: 84960120319     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000231     Document Type: Review

References (68)

1. Institute of Medicine. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Washington DC: National Academies Press; 2011.
2. Brown GR, Jones KT. Racial health disparities in a cohort of 5135 transgender veterans. J Racial Ethn Health Disparities 2014; 1:257-266.
3. Brown GR, Jones KT. Mental health and medical outcome disparities in 5135 transgender veterans receiving healthcare in the Veterans Health Administration: A case-control study. Baltimore, MD: Proceedings of the 32nd Annual Meeting of the Gay and Lesbian Medical Association; 2014.
4. Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5135 transgender veterans. Breast Cancer Res Treat 2015; 149:191-198.
5. Brown GR, Jones KT. Mental health and medical outcome disparities in 5135 transgender veterans receiving healthcare in the Veterans Health Administration: A case-control study. LBGT Health 2015. [Epub ahead of print]
6. Blosnich JR, Brown GR, Shipherd JC, et al. Prevalence of gender identity disorder and suicide risk among transgender veterans utilizing Veterans Health Administration care. Am J Public Health 2013; 103:e27-e32.
7. Blosnich JR, Brown GR, Sybil W, et al. Mortality among veterans with transgender-related diagnoses in the Veterans Health Administration, FY2000-2009. LGBT Health 2014; 1:269-276.
8. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender nonconforming people, 7th version. Int J Transgend 2012; 13:165-232.
9. Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol 2015; 2:55-60.
10. Dhejne C, Lichtenstein P, Boman M, et al. Long-Term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS One 2011; 6:e16885.
11. Asscheman H, Giltay EJ, Megens JA, et al. A long-Term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635-642.
12. Asscheman H, TSjoen GG, Gooren LJ. Morbidity in cross-sex hormone-Treated transgender people. Joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO; 24 June 2014. https://endo.confex. com/endo/2014endo/webprogram/Paper14354.html [Accessed 23 October 2015]. Large US-European retrospective study examining comorbid health conditions and morbidity seen with hormone therapy.
13. Rotondi NK, Bauer GR, Travers R, et al. Depression in male-To-female transgenderOntarians: results from the Trans PULSE Project. Can J Commun Ment Health 2012; 30:113-133.
14. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health 2013; 103:943-951.
15. Heylens G, Elaut E, Baudewijntje PC, et al. Psychiatric characteristics in transsexual individuals: multicentre study in four European countries. Br J Psychiatry 2014; 204:151-156.
16. Colizzi M, Costa R, Todarello O. Transsexual patients psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. Psychoneuroendocrinology 2014; 39:65-73.
17. Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, et al. Hormone-Treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology 2012; 37:662-670.
18. Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: A systematic review and meta-Analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010; 72:214-231.
19. Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO; 24 June 2014. https://endo.confex.com/endo/2014endo/webprogram/Paper14354.htm [Accessed 23 October 2015].
20. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: A case-control study. Eur J Endocrinol 2013; 169:471-478.
21. Wierckx K, Mueller S, Weyers S, et al. Long-Term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9:2641-2651.
22. Asscheman H, Tsjoen G, Lemaire A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-To-female transsexual subjects: A review. Andrologia 2014; 46:791-795.
23. LalibertéF, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18:1052-1059.
24. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007; 115:840-845.
25. Mueller A, Kiesewetter F, Binder H, et al. Long-Term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-To-male transsexuals. J Clin Endocrinol Metab 2007; 92:3470-3475.
26. Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-Analyses. Clin Endocrinol (Oxf) 2010; 72:1-10.
27. Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol 2014; 170:809-819.
28. Elbers JMH, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58:562-571.
29. Colizzi M, Costa R, Scaramuzzi F, et al. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2 year follow-up study. J Psychosom Res 2015; 78:399-406.
30. Deutsch M, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol 2015; 125:605-610. Rare US prospective study on short-Term metabolic effects of hormone therapy.
31. Wierckx K, Van Caenegem E, Schreiner, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-Time follow-up: results from the European Network for the Investigation of Gender Incongruence. J Sex Med 2014; 11:1999-2011.
32. Ott J, Aust S, Promberger R, et al. Cross-sex hormone therapy alters the serum lipid profile: A retrospective cohort study in 169 transsexuals. J Sex Med 2011; 8:2361-2369.
33. Pelusi C, Costantino A, Martelli V, et al. Effects of three different testosterone formulations in female-To-male transsexual persons. J Sex Med 2014; 11:3002-3011.
34. Chandra P, Basra SS, Chen TC, Tangpricha V. Alterations in lipids and adipocyte hormones in female-To-male transsexuals. Int J Endocrinol 2010; Article ID 945053. doi:101155/2010/945053.
35. Goodrum BA. The effects of long-Term testosterone use on lipid-related cardiovascular risk factors among FtM patients. Int J Transgend 2014; 15:164-172.
36. Gooren LJ, van Trotsenburg MAA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013; 10:3129-3134.
37. Brown GR. Breast cancer in transgender veterans: A ten-case series. LGBT Health 2015; 2:77-80.
38. Molokwu CN, Appelbaum JS, Miksad RA. Detection of prostate cancer following gender reassignment. BJU Int 2008; 101:259-1259.
39. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J 2013; 7:E544-E546.
40. Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-To-female transsexual persons treated with oestrogens. Andrologia 2014; 46:1156-1160.
41. Urban RR, Nelson NHT, Kapp DS. Gynecologic malignancies in female-Tomale transgender patients: The need of original gender surveillance. Am J Obstet Gynecol 2011; 204:e9-e12.
42. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159:197-202.
43. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-To-male transsexual persons after longterm cross-sex hormonal therapy. J Clin Endocrinol Metab 2012; 97:2503-2511.
44. Van Caenegem E, Wierckx K, Taes Y, et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol 2015; 172:163-171.
45. Van Kesteren P, Lips P, Gooren LJ, et al. Long-Term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998; 48:347-354.
46. Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-To-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 2013; 54:92-97.
47. Costantino A, Cerpolini S, Alvisi S, et al. A prospective study on sexual function and mood in female-To-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013; 39:321-335.
48. Bouman MB, Zeijl MC, Buncamper ME, et al. Intestinal vaginoplasty revisited: A review of surgical techniques, complications, and sexual function. J Sex Med 2014; 11:1835-1847.
49. Davis SA, Meier SC. Effects of testosterone treatment and chest reconstruction surgery on mental health and sexuality in female-To-male transgender people. Int J Sex Health 2014; 26:113-128.
50. Coulter RWS, Kenst KS, Bowen DJ. Research funded by the National Institutes of Health on the health of lesbian, gay, bisexual, and transgender populations. Am J Public Health 2014; 104:e105-e112.
51. Gelfer MP, Tice RM. Perceptual and acoustic outcomes of voice therapy for male-To-female transgender individuals immediately after therapy and 15 months later. J Voice 2013; 27:335-347.
52. Gelfer MP, Van Dong BR. A preliminary study on the use of vocal function exercises to improve voice in male-To-female transgender clients. J Voice 2013; 27:321-334.
53. Cosyns M, Van Borsel J, Wierckx K, et al. Voice in female-To-male transsexual persons after long-Term androgen therapy. Laryngoscope 2014; 124:1409-1414.
54. Horbach SE, Bouman MB, Smit JM, et al. Outcome of vaginoplasty in male-Tofemale transgenders: A systematic review of surgical techniques. J Sex Med 2015; 12:1499-1512.
55. Rossi Neto R, Hintz F, Krege S, et al. Gender reassignment surgery: A 13 year review of surgical outcomes. Eur Urol Suppl 2013; 12:e559.
56. Bergoglio MT, Gómez-Balaguer M, Folch EA, et al. Symptomatic meningioma induced by cross-sex hormone treatment in a male-To-female transsexual. Endocrinol Nutr 2013; 60:264-267.
57. Borghei-Razavi H, Fragoza-Padilla V, Hargus G, et al. Meningioma: The unusual growth in a transsexual patient after estrogen-progesterone therapy. SOJ Neurol 2014; 1:1-3.
58. Cunha FS, Domenice S, Camara VL, et al. Diagnosis of prolactinoma in two male-To-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia 2014; 47:680-684.
59. Chan KL, Mok CC. Development of systemic lupus erythematosus in a maleto-female transsexual: The role of sex hormones revisited. Lupus 2013; 22:1399-1402.
60. Zubiaurre-Elorza L, Junque C, Gómez-Gil E, Guillamon A. Effects of cross-sex hormone treatment on cortical thickness in transsexual individuals. J Sex Med 2014; 11:1248-1261.
61. Zubiaurre-Elorza L, Junque C, Gómez-Gil E, et al. Cortical thickness in untreated transsexuals. Cereb Cortex 2013; 23:2855-2862.
62. Deutsch MB, Keatley J, Sevelius J, Shade SB. Collection of gender identity data using electronic medical records: survey of current end-user practices. J Assoc Nurses AIDS Care 2014; 6:657-663.
63. Deutsch MB. Use of the informed consent model in the provision of cross-sex hormone therapy: A survey of the practices of selected clinics. Int J Transgend 2012; 13:140-146.
64. Reisner SL, Bradford J, Hopwood R, et al. Comprehensive transgender healthcare: The gender affirming clinical and public health model of Fenway Health. J Urban Health 2015; 92:584-592.
65. Unger CA. Care of the transgender patient: A survey of gynecologists current knowledge and practice. J Womens Health 2015; 24:114-118.
66. Grant JM, Mottet L, Tanis JE, et al. Injustice at every turn: A report of the National Transgender Discrimination Survey. Washington DC: National Center for Transgender Equality; 2011.
67. de Haan G, Santos GM, Arayasirikul S, Raymond HF. Nonprescribed hormone use and barriers to care for transgender women in San Francisco. LGBT Health 2015; 2:313-323.
68. Mepham N, Bouman WP, Arcelus J, et al. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med 2014; 11:2995-3001.